Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Are The Future Growth Projections For The HER2-Positive Breast Cancer Market Size?

In the past few years, the market size for her2-positive breast cancer has seen robust growth. The market value is projected to increase from $10.21 billion in 2024 to $10.93 billion in 2025, showing a compound annual growth rate (CAGR) of 7.0%. Factors contributing to this growth in the historic period include enhanced early detection and diagnosis, heightened awareness of HER2-positive subtypes, an upsurge in research and development investments, an increased preference for precision medicine, and a rising priority on improving patient outcomes.

The market size for her2-positive breast cancer is anticipated to rise robustly in the imminent years, reaching $14.3 billion in 2029, propelled by a compound annual growth rate (CAGR) of 6.9%. Factors contributing to this upward shift during the forecast period include the escalating demand for liquid biopsy for non-invasive supervision, increasing uptake of combination treatments, a heightened emphasis on immunotherapies and innovative drug formulations, growing application of liquid biopsy methods for noninvasive supervision, and the surge in specialized cancer treatment centers. Key trends throughout the forecast period encompass advancements in targeted therapies, development of novel formulations, breakthroughs in immunotherapy methods, the progress of innovative HER2-targeted therapies, and improvements made in biomarkers for more precise patient stratification.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20832&type=smp

Which Factors Are Steering Growth In The HER2-Positive Breast Cancer Market?

The robust uptake of immunotherapy is anticipated to fuel the expansion of the HER2-positive breast cancer market in the foreseeable future. Immunotherapy is a form of medical treatment that boosts or alters the natural capacity of the immune system to combat conditions like cancer, infections, and autoimmune disorders. The use of immunotherapy is credited to its potential to augment the immune system’s competence to detect and eradicate cancer cells, yielding superior effectiveness and less adverse effects compared to conventional therapies. Immunotherapy supports HER2-positive breast cancer by bolstering the body’s immune system to recognize and attack HER2-overexpressing cancer cells, enhancing treatment results and diminishing the likelihood of relapse. For instance, in July 2023, as reported by the American Association for Cancer Research, a US-based organization, the FDA gave approval to 11 immune checkpoint inhibitors (ICIs) in 2023, with at least one ICI approved for the treatment of 20 diverse cancer types and for any solid tumor displaying specific molecular traits. Hence, the robust uptake of immunotherapy contributes to the expansion of the HER2-positive breast cancer market.

How Is The HER2-Positive Breast Cancer Market Organized By Different Segments?

The her2-positive breast cancermarket covered in this report is segmented –

1) By Treatment Type: Targeted Therapy; Chemotherapy; Endocrine Therapy; Immunotherapy; Other Treatment Types

2) By Route Of Administration: Parenteral; Oral; Other Route Of Administrations

3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

4) By End User: Hospitals; Homecare; Specialty Clinics; Other End User

Subsegments:

1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab); Tyrosine Kinase Inhibitors (TKIs); Antibody-Drug Conjugates (ADC); Small Molecule Inhibitors

2) By Chemotherapy: Anthracycline-based Chemotherapy; Taxane-based Chemotherapy; Platinum-based Chemotherapy; Combination Chemotherapy Regimens

3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs); Aromatase Inhibitors; Estrogen Receptor Antagonists; Estrogen Deprivation Therapy

4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors); Monoclonal Antibodies for Immune Modulation; Cancer Vaccines

5) By Other Treatment Types: Radiation Therapy; Stem Cell Therapy; Hyperthermia Treatment; Gene Therapy; Surgical Interventions (Mastectomy, Breast Conserving Surgery)

What Current And Upcoming Trends Are Shaping The HER2-Positive Breast Cancer Market?

Leading corporations in the HER2-positive breast cancer industry are investing their efforts in the creation of progressive therapies like HER2-focused antibody-drug conjugates (ADCs), aimed at improving and simplifying patient treatment. These targeted cancer treatments fuse a HER2 specific antibody with a toxic drug, enabling direct delivery to HER2-positive cancer cells, resulting in a more successful treatment. For example, AstraZeneca India Pharma Ltd., a biopharmaceutical firm from India, unveiled Trastuzumab deruxtecan in January 2024. This state-of-the-art therapy, a product of the joint efforts of AstraZeneca and Daiichi Sankyo, is a HER2-focused ADC that delivers a toxic drug straight to HER2-positive cancer cells, providing patients a more focused and potent therapy.

Who Are The Most Influential Companies In The HER2-Positive Breast Cancer Market?

Major companies operating in the HER2-positive breast cancer market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis International AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Daiichi Sankyo Co. Ltd., Incyte Corporation, BioNTech SE, MacroGenics Inc., CStone Pharmaceuticals Co. Ltd., Sorrento Therapeutics Inc., Syndax Pharmaceuticals Inc., Fate Therapeutics Inc., Ambrx Biopharma Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/her2-positive-breast-cancer-global-market-report

Which Region Dominates The HER2-Positive Breast Cancer Market Today?

North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=20832&type=smp

Browse Through More Reports Similar to the Global HER2-Positive Breast Cancer Market 2025, By The Business Research Company

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Breast Cancer Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-diagnostics-global-market-report

Breast Imaging Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-imaging-devices-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model